A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Brian A. Walker, Konstantinos Mavrommatis, Christopher P. Wardell, T. Cody Ashby, Michael Bauer, Faith Davies, Adam Rosenthal, Hongwei Wang, Pingping Qu, Antje Hoering, Mehmet Samur, Fadi Towfic, Maria Ortiz, Erin Flynt, Zhinuan Yu, Zhihong Yang, Dan Rozelle, John Obenauer, Matthew Trotter, Daniel Auclair & 19 others Jonathan Keats, Niccolo Bolli, Mariateresa Fulciniti, Raphael Szalat, Phillipe Moreau, Brian Durie, A. Keith Stewart, Hartmut Goldschmidt, Marc-Steffen Raab, Hermann Einsele, Pieter Sonneveld, Jesus San Miguel, Sagar Lonial, Graham H. Jackson, Kenneth C. Anderson, Herve Avet-Loiseau, Nikhil Munshi, Anjan Thakurta, Gareth Morgan

Research output: Contribution to journalArticle

  • 6 Citations

Abstract

Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.

LanguageEnglish (US)
Pages159-170
Number of pages12
JournalLeukemia
Volume33
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Disease-Free Survival
Multiple Myeloma
Survival
Genome
Exome
DNA
Proportional Hazards Models
Cytogenetics
Therapeutics
Gene Expression
Population

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., ... Morgan, G. (2019). A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia, 33(1), 159-170. https://doi.org/10.1038/s41375-018-0196-8

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. / Walker, Brian A.; Mavrommatis, Konstantinos; Wardell, Christopher P.; Ashby, T. Cody; Bauer, Michael; Davies, Faith; Rosenthal, Adam; Wang, Hongwei; Qu, Pingping; Hoering, Antje; Samur, Mehmet; Towfic, Fadi; Ortiz, Maria; Flynt, Erin; Yu, Zhinuan; Yang, Zhihong; Rozelle, Dan; Obenauer, John; Trotter, Matthew; Auclair, Daniel; Keats, Jonathan; Bolli, Niccolo; Fulciniti, Mariateresa; Szalat, Raphael; Moreau, Phillipe; Durie, Brian; Stewart, A. Keith; Goldschmidt, Hartmut; Raab, Marc-Steffen; Einsele, Hermann; Sonneveld, Pieter; San Miguel, Jesus; Lonial, Sagar; Jackson, Graham H.; Anderson, Kenneth C.; Avet-Loiseau, Herve; Munshi, Nikhil; Thakurta, Anjan; Morgan, Gareth.

In: Leukemia, Vol. 33, No. 1, 01.01.2019, p. 159-170.

Research output: Contribution to journalArticle

Walker, BA, Mavrommatis, K, Wardell, CP, Ashby, TC, Bauer, M, Davies, F, Rosenthal, A, Wang, H, Qu, P, Hoering, A, Samur, M, Towfic, F, Ortiz, M, Flynt, E, Yu, Z, Yang, Z, Rozelle, D, Obenauer, J, Trotter, M, Auclair, D, Keats, J, Bolli, N, Fulciniti, M, Szalat, R, Moreau, P, Durie, B, Stewart, AK, Goldschmidt, H, Raab, M-S, Einsele, H, Sonneveld, P, San Miguel, J, Lonial, S, Jackson, GH, Anderson, KC, Avet-Loiseau, H, Munshi, N, Thakurta, A & Morgan, G 2019, 'A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis', Leukemia, vol. 33, no. 1, pp. 159-170. https://doi.org/10.1038/s41375-018-0196-8
Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 Jan 1;33(1):159-170. https://doi.org/10.1038/s41375-018-0196-8
Walker, Brian A. ; Mavrommatis, Konstantinos ; Wardell, Christopher P. ; Ashby, T. Cody ; Bauer, Michael ; Davies, Faith ; Rosenthal, Adam ; Wang, Hongwei ; Qu, Pingping ; Hoering, Antje ; Samur, Mehmet ; Towfic, Fadi ; Ortiz, Maria ; Flynt, Erin ; Yu, Zhinuan ; Yang, Zhihong ; Rozelle, Dan ; Obenauer, John ; Trotter, Matthew ; Auclair, Daniel ; Keats, Jonathan ; Bolli, Niccolo ; Fulciniti, Mariateresa ; Szalat, Raphael ; Moreau, Phillipe ; Durie, Brian ; Stewart, A. Keith ; Goldschmidt, Hartmut ; Raab, Marc-Steffen ; Einsele, Hermann ; Sonneveld, Pieter ; San Miguel, Jesus ; Lonial, Sagar ; Jackson, Graham H. ; Anderson, Kenneth C. ; Avet-Loiseau, Herve ; Munshi, Nikhil ; Thakurta, Anjan ; Morgan, Gareth. / A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. In: Leukemia. 2019 ; Vol. 33, No. 1. pp. 159-170.
@article{a0238498961341478556fa013949eed1,
title = "A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis",
abstract = "Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4{\%} and 25.2{\%}, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3{\%} for PFS and 46.5{\%} for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1{\%} of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.",
author = "Walker, {Brian A.} and Konstantinos Mavrommatis and Wardell, {Christopher P.} and Ashby, {T. Cody} and Michael Bauer and Faith Davies and Adam Rosenthal and Hongwei Wang and Pingping Qu and Antje Hoering and Mehmet Samur and Fadi Towfic and Maria Ortiz and Erin Flynt and Zhinuan Yu and Zhihong Yang and Dan Rozelle and John Obenauer and Matthew Trotter and Daniel Auclair and Jonathan Keats and Niccolo Bolli and Mariateresa Fulciniti and Raphael Szalat and Phillipe Moreau and Brian Durie and Stewart, {A. Keith} and Hartmut Goldschmidt and Marc-Steffen Raab and Hermann Einsele and Pieter Sonneveld and {San Miguel}, Jesus and Sagar Lonial and Jackson, {Graham H.} and Anderson, {Kenneth C.} and Herve Avet-Loiseau and Nikhil Munshi and Anjan Thakurta and Gareth Morgan",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41375-018-0196-8",
language = "English (US)",
volume = "33",
pages = "159--170",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

AU - Walker, Brian A.

AU - Mavrommatis, Konstantinos

AU - Wardell, Christopher P.

AU - Ashby, T. Cody

AU - Bauer, Michael

AU - Davies, Faith

AU - Rosenthal, Adam

AU - Wang, Hongwei

AU - Qu, Pingping

AU - Hoering, Antje

AU - Samur, Mehmet

AU - Towfic, Fadi

AU - Ortiz, Maria

AU - Flynt, Erin

AU - Yu, Zhinuan

AU - Yang, Zhihong

AU - Rozelle, Dan

AU - Obenauer, John

AU - Trotter, Matthew

AU - Auclair, Daniel

AU - Keats, Jonathan

AU - Bolli, Niccolo

AU - Fulciniti, Mariateresa

AU - Szalat, Raphael

AU - Moreau, Phillipe

AU - Durie, Brian

AU - Stewart, A. Keith

AU - Goldschmidt, Hartmut

AU - Raab, Marc-Steffen

AU - Einsele, Hermann

AU - Sonneveld, Pieter

AU - San Miguel, Jesus

AU - Lonial, Sagar

AU - Jackson, Graham H.

AU - Anderson, Kenneth C.

AU - Avet-Loiseau, Herve

AU - Munshi, Nikhil

AU - Thakurta, Anjan

AU - Morgan, Gareth

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.

AB - Patients with newly diagnosed multiple myeloma (NDMM) with high-risk disease are in need of new treatment strategies to improve the outcomes. Multiple clinical, cytogenetic, or gene expression features have been used to identify high-risk patients, each of which has significant weaknesses. Inclusion of molecular features into risk stratification could resolve the current challenges. In a genome-wide analysis of the largest set of molecular and clinical data established to date from NDMM, as part of the Myeloma Genome Project, we have defined DNA drivers of aggressive clinical behavior. Whole-genome and exome data from 1273 NDMM patients identified genetic factors that contribute significantly to progression free survival (PFS) and overall survival (OS) (cumulative R2 = 18.4% and 25.2%, respectively). Integrating DNA drivers and clinical data into a Cox model using 784 patients with ISS, age, PFS, OS, and genomic data, the model has a cumlative R2 of 34.3% for PFS and 46.5% for OS. A high-risk subgroup was defined by recursive partitioning using either a) bi-allelic TP53 inactivation or b) amplification (≥4 copies) of CKS1B (1q21) on the background of International Staging System III, comprising 6.1% of the population (median PFS = 15.4 months; OS = 20.7 months) that was validated in an independent dataset. Double-Hit patients have a dire prognosis despite modern therapies and should be considered for novel therapeutic approaches.

UR - http://www.scopus.com/inward/record.url?scp=85049511313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049511313&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0196-8

DO - 10.1038/s41375-018-0196-8

M3 - Article

VL - 33

SP - 159

EP - 170

JO - Leukemia

T2 - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -